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Diabetes insipidus in the diagnosis 
of polyuria
Abstract
Diabetes insipidus is a rare condition, whereas polyuria may be a symptom of numerous other ailments. 
Polyuria intensifies thirst (polydipsia), which appears to be a natural reaction to an excessive loss of water 
in the organism. Before diagnosing rare conditions, hypoglycaemia and kidney failure must be excluded. 
Borderline cases must consult with an endocrinology specialist.
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Introduction 
Diabetes insipidus (DI) is a rare illness caused 
either by vasopressin deficiency (central diabetes in-
sipidus, also known as neurohormonal) or by a lack 
of renal canal sensitivity to vasopressin (nephrogenic 
diabetes insipidus) [1].
The prevalence of diabetes insipidus is one case 
per 25,000 population, with no sex difference. Cen-
tral diabetes insipidus is the result of damage to 
the supraoptic nuclei in the hypothalamus, where 
vasopressin is secreted. In such a case, the damage 
leads to permanent DI. In rare cases, for example 
when a patient suffers either post-operative in-
fundibulum hypothalamus damage or rear hypotha-
lamus lobe damage (the area which transports and 
stores the neurohormone), the disorder may be 
a passing matter. Neurohormonal diabetes insip-
idus is caused in most cases by:
 — hypothalamus tumours (craniopharyngiomas, 
invasive pituitary macroadenomas);
 — hypothalamic-pituitary area inflammation;
 — injury;
 — post-operative condition or post-radiotherapy 
condition (RTH);
 — ectopic secretion by other malignant tumours;
 — empty sella syndrome [1, 2].
Moreover, neurohormonal diabetes insipidus may 
be idiophatic, either genetically or immunologically 
based. 
Nephrogenic diabetes insipidus is caused by a ge-
netic defect in the vasopressin receptors in the kid-
neys and occurs only in males. It may also occur in 
either acquired neuropathies, such as hypercalcaemia 
(e.g. hyperactive parathyroid glands) or hyperkalae-
mia (e.g. primary aldosteronism). 
The clinical picture of diabetes insipidus is influ-
enced by the following symptoms:
 — excessive thirst (polydipsia);
 — polyuria (passing > 4 litres of urine a day);
 — low specific gravity of the urine (< 1,005; so-called 
diluted urine);
 — frequent nightly urination and quenching of 
thirst;
 — additionally, symptoms of hypothalamic-pituitary 
tumour may occur [1].
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Diagnosis of the disorder is determined by 
a two-stage dehydration test and a vasopressin test. 
First of all, this allows the exclusion of psychogen-
ic-based polydipsia (psychogenic diabetes insipidus, 
thirst neurosis), when polyuria is caused by habitual 
excessive fluid intake. Furthermore, the test ena-
bles us to determine whether we are dealing with 
neurohormonal diabetes insipidus or nephrogenic 
diabetes insipidus (Table 1). The test is carried out 
in hospital, prior to excluding polyuria in diabetes. 
The dehydration test is a urine concentration 
test which consists of the complete restriction of 
fluid intake. The test begins in the morning and the 
patient is weighed every 30 minutes. Simultaneously, 
the specific gravity (or osmolarity) of successive sam-
ples is calculated, as well as the plasma osmolarity. 
The test continues as long as the body mass reduc-
es by 3% of the initial weight proportion or the con-
centration of sodium in the blood serum exceeds the 
upper limit of normal. The test usually takes a few 
hours and enables the calculation of the vasopressin 
in the blood serum. In central diabetes insipidus the 
vasopressin concentration is very low, whereas neph-
rogenic diabetes insipidus causes high vasopressin 
concentration. In central DI neither a urine specific 
gravity nor urine osmolarity increase is reported (os-
molarity < 250 mOsm/kg) with a plasma osmolarity 
increase (norm: 275–190 mOsm/kg). On the other 
hand, in psychogenic polydipsia, once vasopressin 
is stimulated, urine specific gravity increases. 
The vasopressin test appears in the second phase 
of the diagnostic process. It differentiates central 
diabetes insipidus from nephrogenic diabetes insip-
idus. In the dehydration test, as soon as successive 
urine samples do not reveal significant differences in 
osmolarity (< 10%), a vasopressin analog is admin-
istered, either orally (0.2 mg) or intranasally (20 μg). 
Only then can the specific gravity, osmolarity and 
volume of the successive portions of urine be calcu-
lated. If the urine concentration increases by at least 
50% after desmopressin is administered, this indi-
cates that we are dealing with central diabetes insip-
idus. However, a persistent decrease in urine specific 
gravity and its osmolarity suggests nephrogenic dia-
betes insipidus. In a case where a magnetic resonance 
imaging (MRI) of the head has not been performed 
on a patient before the test, such a procedure must 
absolutely be conducted [1]. 
The treatment of diabetes insipidus depends upon 
its cause. In the case that central diabetes insipi-
dus is a symptom of a large hormonally inactive 
pituitary adenoma, what appears to treat the cause 
is a neurosurgical procedure through the transsphe-
noidal route. On the other hand, in the symptomatic 
treatment of diabetes insipidus we employ a substi-
tution which involves an individually calculated dose 
of a long-acting vasopressin analog (desmopressin). 
The substance is administered via the intranasal or 
oral route. The effectiveness of the treatment can be 
evaluated easily: as soon as the clinical symptoms dis-
appear, plasma osmolarity returns to normal and the 
sodium in the serum normalizes. If diabetes insipi-
dus results from acquired kidney damage, care of the 
underlying illness and symptomatic treatment seem 
to be essential (with appropriate hydration and fluid 
deficiency correction). Any symptoms of diabetes in-
sipidus caused by electrolyte disturbances disappear 
as soon as the disturbances are equalized. In diabe-
tes insipidus resulting from genetic defects in the 
vasopressin receptors, what appears to be a basis for 
treatment is an appropriate diet with sodium restric-
tion and a thiazide diuretic. If there is a partial sen-
Table 1. Differential diagnosis of psychogenic diabetes, central diabetes insipidus and nephrogenic 
diabetes insipidus based on the results of dehydration and vasopressin tests 
Thirst neurosis Central diabetes insipidus 
(neurohormonal)
Nephrogenic 
diabetes insipidus
Dehydration test (urine concentration test)
Urine specific gravity [g/ml] Gradually increases < 1,005 < 1,005
Urine osmolarity Gradually increases 
to meet the norm
< 250 mOsm/kg < 250 mOsm/kg
Vasopressin concentration in the plasma Initially low, increases Low High
Vasopressin test (desmopressin 0.2 mg PO)
Urine specific gravity There is no indication 
for the test*
Increases by ≥ 50% 
(200–400%)
Low, does not increase
*due to satisfactory results of the dehydration test
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sitivity to vasopressin, large doses of hormone seem 
appropriate [1]. Prognosis depends upon the cause 
of the disorder but is usually auspicious. Even un-
treated diabetes insipidus does not pose any threat 
to a patient’s life, providing the patient drinks plenty 
of fluids. In cases of unconscious patients (such 
as those with an injury or after brain area surgery) 
and patients with a thirst disorder, fluid balance 
should be a particular focus. Substitution treatment 
allows patients to perform normal life activities with-
out troublesome symptoms of the illness. 
Case report
On 2 November 2010, a 65-year-old woman pa-
tient with tumours of both kidneys (potentially 
malignant) was admitted after an incident of gastro-
intestinal bleeding to the ward of the day hospice in 
Bydgoszcz with symptomatic treatment continuation 
and further care in mind. Moreover, the patient suf-
fered depressive disorders, bipolar disorder, second-
ary anaemia and diabetes mellitus Type 2 treated 
with insulin. Lesions in both kidneys had been de-
tected two years before and since then the patient 
had been closely monitored by urologists at the 
Oncology Centre. She did not qualify for an opera-
tion. While she was monitored, the doctors observed 
normal creatinine values. On 25 October 2010, when 
in the surgical unit of a City Hospital, she underwent 
a CAT scan on her head, which demonstrated cerebral 
oedema features, and pituitary gland extension to 
13 mm (suspicion of a pituitary gland tumour).
When the patient was admitted to the unit, her 
condition was very serious. She was barely con-
scious and illogical. Additionally, she experienced se-
vere renal failure (creatinine 4.9 mg/dl) in the polyuria 
phase with diuresis of 3–5 l/day and erratic BMs. The 
patient reported dyspnoea and pain in her abdominal 
cavity. A clinical examination revealed low sensitivity 
of the abdominal membranes and moderate rest 
dyspnoea, without features of stasis over the lung 
fields. Owing to the malady and the medical condi-
tion of the patient, we administered the following 
procedures: subcutaneous hydration in accordance 
with fluid balance, diuresis forced by furosemide 
(40 mg/day IV), and 2.5 mg of hypodermically injected 
morphine in the case of either acute pain or dyspnoea. 
Omeprazole (20 mg) continued to be administered 
and the steroidotherapy (dexamethasone adminis-
tered intravenously, 8 mg/day) intensified due to the 
cerebral oedema displayed in the CAT scan images. 
Soon, her medical condition improved and this facili-
tated conscious contact with the patient. A creatinine 
concentration decrease was reported and the volume 
touched the norm (4.9 Æ 1.1 mg/dl) without ionic 
disturbances. However, polyuria and excessive thirst 
persisted (up to 5 l/d) and this provided the basis for 
maintaining a Foley catheter in the urinary bladder. 
Owing to obstinate astriction, manual removal of an 
impacted stool was necessary but as soon as intensi-
fied pharmacological treatment was implemented, 
bowel evacuation normalized. Badly-managed gly-
caemy and intense hunger were causes of a dexa-
methasone dose reduction (to 2–2–0 mg PO). The 
patient’s medical condition was stabilized. However, 
sluggishness and malaise appeared and venlafaxine 
was administered with a morning dosage of 150 mg. 
Additionally, the thyroid hormone level was tested 
and the results revealed the following: TSH 0.79 
μIU/ml (N: 0.27–4.20), FT3 1.1 pmol/l (N: 3.1–6.8), 
FT4 0.7 pmol/l (N: 12–22). Secondary hypothyreo-
sis was identified and L-thyroxine was administered 
with an initial dosage of 25 μg/day. Since pituitary 
adenoma was diagnosed, the patient was assessed 
by an endocrinologist, who confirmed secondary hy-
pothyreosis and increased the L-thyroxine dosage to 
50 μg/day. The specialist found neither Cushing’s syn-
drome symptoms nor acromegaly. To determine and 
differentiate the causes of the intense thirst and 
polyuria, he decided to conduct a further investigation 
to calculate urine specific gravity. When this turned 
out to be low (1,003 g/ml), 0.1 mg of desmopressin 
was implemented, which led to diuresis reduction (to 
1.75 l within one day) and the urine specific gravity 
increased. Such treatment facilitated catheter removal 
from the urinary bladder, which significantly improved 
the quality of the patient’s everyday life. Moreover, 
we applied rehabilitation, during which the patient 
performed both active and passive activities and main-
tained a sitting position. We also attempted a change 
from a lying to a standing position. She then tried to 
walk with assecuration. The patient was discharged 
in good condition. 
Discussion
One of the main problems in the aforementioned 
case was excessive urinating. Polyuria occurs if a pa-
tient passes more than 2,500 ml of urine a day and 
it may be a symptom of numerous illnesses. In such 
a case, renal status must be checked, since diuresis may 
result either from uraemia or the polyuria phase of 
acute renal failure. Moreover, hyperglycaemia should 
also be excluded because glycosuria leads to osmotic 
diuresis. Polyuria also accompanies hypercalcaemia 
and psychogenic polydipsia. Finally, polyuria may 
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result from central diabetes insipidus or nephrogenic 
diabetes insipidus (discussed above) [3].
The patient experienced many ailments which 
could have contributed to the polyuria, and what 
follows to polydipsia. Before the patient was admit-
ted to the hospice, she had gastrointestinal bleed-
ing which brought about acute renal failure. The 
descending course of such a dysfunction is polyuria. 
Furthermore, the steroid therapy, administered ow-
ing to suspicion of brain metastasis, together with 
insulin-treated diabetes, led to poorly-managed 
blood sugar which could also have been a cause of 
the polyuria and intense thirst. In addition, the CAT 
scan of her head demonstrated pituitary extension 
and implied a tumour which contributed to central 
diabetes insipidus. The reported case does not allow 
us to elaborate on features of the tumour. However, 
we are inclined to believe that there was metasta-
sis either from the site of disease progression (lack 
of histopathology examination results) or from the 
hormonally inactive adenoma. Metastases to the 
pituitary gland are not frequent (less than 1% of 
patients with neurosurgical recommendations and 
approximately 5% of autopsied patients diagnosed 
with cancer) and usually manifest disseminated 
cancer [4]. Tumours which most often give rise to 
metastases for the organ include breast cancer and 
lung cancer [4, 5]. Metastases are usually located in 
the rear lobe of the pituitary gland or in both frontal 
and rear lobes (84.6% of 201 cases of metastases); 
however, frontal metastases comprise 15.4% of all 
cases [6]. Such locations of metastases make us think 
that their symptoms cause diabetes insipidus [4, 6]. 
A diabetes insipidus diagnosis should be pre-
ceded by a dehydration test. In the reported case, 
the patient was admitted to the hospice in a very bad 
condition. She experienced dehydration symptoms, 
renal failure and unlevelled diabetes and a dehydra-
tion test could have worsened her condition. A urine 
specific gravity calculation seemed a much easier and 
more available test. Since there was a diabetes in-
sipidus suspicion, the test was administered. The 
virtually immediate and good reaction to vasopressin 
analog treatment confirmed the initial diagnosis. 
Desmopressin in the treatment also gave a visible 
effect, since the diuresis and thirst diminished after 
a few hours. Undeniably, this improved the pa-
tient’s comfort and made medical assistance easier. 
A pituitary gland tumour diagnosed with medical 
imaging facilitates a full evaluation of the hormonal 
functions of the organ. In the reported case, the 
patient’s condition restricted examinations to a TSH 
concentration test and a thyroid hormones test. 
Since there were no manifestations of either ac-
romegaly or Cushing’s disease, it was decided to 
abandon tests which would calculate the concen-
tration of growth hormone, ACTH and cortisol. 
Moreover, the patient took dexamethasone, which 
impedes a proper interpretation of pituitary-adrenal 
axis hormone concentration test results.  The na-
ture of the tumour and the spread of the disease are 
not confirmed (the good clinical status of the patient 
and the lack of progression speak against spread); 
it may be an accidentally detected regular pituitary 
adenoma, which would require further diagnos-
tics and perhaps even neurosurgical treatment. Full 
evaluation of the hormonal function of the pituitary 
gland and hypothalamic-pituitary area imaging by 
means of a scanning procedure may be considered, 
providing the patient’s condition normalizes, and 
depends upon further progression of the underlying 
disease. At times, numerous symptoms and treat-
ment are reflected in the life span of patients under 
palliative care. The kind of acute renal failure treat-
ment the patient was given was neither expensive 
nor troublesome and once her clinical condition nor-
malized and a low-cost test had been recommended, 
her condition improved considerably. Since then, she 
has reached nearly full capacity after home rehabili-
tation, which has enabled her to function normally. 
After a few months, due to the severity of polyuria, 
a hospice doctor increased the dose of desmopressin 
which led to urine output reduction to 1.5 l a day. Full 
diagnostics of the pituitary hormone are planned to 
be conducted at the Endocrinology Outpatient Clinic 
at the Oncology Centre in Bydgoszcz.
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